Recent Updates
Recently added Catalysts
INM

NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2022 Annual General Meeting Vancouver, BC

Key Takeaway: InMed Announces Results of 2022 Annual General Vancouver, BC - December 15, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today co

Full Press Release Details

InMed Announces Results of 2022 Annual General
Vancouver, BC - December 15, 2022 -
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical
research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting
of shareholders held on December 15, 2022 (the "Meeting"), all of the matters put forward before shareholders for consideration
and approval as set out in InMed's notice of meeting and management information circular, dated October 28, 2022, were approved
by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting
of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are
Votes For Withheld Votes
Director Number Percentage Number Percentage
Eric A. Adams 159,223 94.90 % 8,559 5.10 %
Andrew Hull 158,282 94.34 % 9,500 5.66 %
Janet Grove 162,246 96.70 % 5,536 3.30 %
Bryan Baldasare 160,764 95.82 % 7,018 4.18 %
Nicole Lemerond 162,174 96.66 % 5,608 3.34 %
InMed filed a report of voting results on SEDAR
at www.sedar.com on December 15, 2022.
InMed Pharmaceuticals is a global leader
in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment
of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce
cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.
Vice President, Investor Relations
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: being a global leader in the manufacturing and development
of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.
Last updated: Dec 15, 2022